# Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05502237/  
OnCo record `nct05502237` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Domvanalimab in non-small-cell lung cancer, active and no longer recruiting.

## Summary

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05502237, led by Gilead Sciences with Arcus Biosciences, and active but no longer recruiting on the registry. Official title: A Randomised, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumour Aberrations. Planned enrolment is 1021 participants (actual). The study started in 2022-10-12 and primary completion is expected in 2028-06. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: STAR-121
- Tags: ctgov-ingest
- Registry id: NCT05502237
- Phase: 3
- Setting: A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
- Sponsor: Gilead Sciences
- Enrolled: 1021

## Sources

- ClinicalTrials.gov NCT05502237: https://clinicaltrials.gov/study/NCT05502237

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/)
- drugs: [Domvanalimab](https://onco.cc/drugs/domvanalimab/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct05502237.json